Strides Pharma Science · NSE: STAR · BSE: 532531

Q3 FY26 results · Oct–Dec 2025

Strides Pharma Science reported revenue from operations of ₹1,194.65 crore (up 3.6% from Q3 FY25) and net profit of ₹208.12 crore (up 131.1% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY26	Q3 FY25	YoY	Q2 FY26	QoQ
Revenue from operations	1,194.65	1,153.67	+3.6%	1,220.83	−2.1%
Other income	106.86	5.62	19x	27.14	+293.7%
Total income	1,301.51	1,159.28	+12.3%	1,247.97	+4.3%
Profit before share of associates & JVs and tax	245.51	112.89	+117.5%	154.16	+59.2%
Share of profit/(loss) of associates & JVs	(0.03)	0.95		(1.05)
Net profit for the period	208.12	90.04	+131.1%	131.52	+58.2%
Attributable to shareholders of the company	202.11	87.95	+129.8%	127.53	+58.5%
EPS, basic (₹)	21.93	9.56	+129.4%	13.84	+58.5%
Net margin (%)	17.4	7.8		10.8

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY26	Q3 FY25	YoY	Q2 FY26	QoQ
Revenue from operations	553.63	550.92	+0.5%	522.15	+6.0%
Other income	103.24	2.43	43x	14.09	+632.6%
Total income	656.88	553.35	+18.7%	536.24	+22.5%
Profit before tax	134.80	21.38	+530.6%	25.39	+431.0%
Net profit for the period	121.89	14.94	+716.0%	32.04	+280.4%
EPS, basic (₹)	13.22	1.62	+716.0%	3.48	+279.9%
Net margin (%)	22.0	2.7		6.1

Consolidated

Filed with BSE: 30 Jan 2026, 17:10 IST
Board meeting: 30 Jan 2026
Period: 01 Oct 2025 to 31 Dec 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 30 Jan 2026, 17:10 IST
Board meeting: 30 Jan 2026
Period: 01 Oct 2025 to 31 Dec 2025
Review status: Unaudited
Source: XBRL filing on BSE